Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.06%
#3 CoW Protocol CoW Protocol +37.63%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +28.04%
#6 Walrus Walrus +22.05%
#7 Codatta Codatta +21.20%
#8 Enso Enso +19.64%
#9 The Black Bull The Black Bull +17.55%
#10 Tutorial Tutorial +14.31%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Rank in Stocks #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Share Price
$0.117
Last synced: 2025-04-04
Market Cap
$2.45M
Change (1 day)
-13.59%
Change (1 year)
0.00%
Country
US
Trade Carmell Therapeutics Corporation (CTCX)

Category

Healthcare
P/S ratio for Carmell Therapeutics Corporation (CTCX)
P/S ratio as of August 2026 TTM: 3.52
According to Carmell Therapeutics Corporation latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.52. At the end of 2023 the company had a P/S ratio of 0.00.
P/S ratio history for Carmell Therapeutics Corporation from 2021 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 3.52 -99.90%
2024 3.48K 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 188.58%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 187.49%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 34.60%
BE